We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

50 hedge funds and large institutions have $12.6M invested in Matinas BioPharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.25% → 0.25% (-0.01%)

7% less capital invested

Capital invested by funds: $13.6M → $12.6M (-$1.01M)

12% less funds holding

Funds holding: 57 → 50 (-7)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

Holders
50
Holders Change
-7
Holders Change %
-12.28%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
10
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$77.6K
2
MWM
Modera Wealth Management
New Jersey
+$47.8K
3
SS
Simplicity Solutions
Minnesota
+$30.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$25.7K
5
Northern Trust
Northern Trust
Illinois
+$8.52K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$125K
2
Jane Street
Jane Street
New York
-$74.4K
3
VF
Virtu Financial
New York
-$72K
4
SIG
Sargent Investment Group
Maryland
-$67.2K
5
BCM
Bridgeway Capital Management
Texas
-$50.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.12M +$77.6K +3,073 +2%
SIG
2
Sargent Investment Group
Maryland
$2.08M -$67.2K -2,661 -3%
BlackRock
3
BlackRock
New York
$1.16M -$125K -4,964 -9%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$848K – – –
NRS
5
Neville Rodie & Shaw
New York
$824K – – –
AWA
6
Arkadios Wealth Advisors
Georgia
$658K – – –
JEST
7
JTC Employer Solutions Trustee
Jersey
$358K – – –
State Street
8
State Street
Massachusetts
$335K – – –
LPL Financial
9
LPL Financial
California
$298K – – –
SCA
10
STALEY CAPITAL ADVISERS
Pennsylvania
$282K – – –
BCM
11
Bridgeway Capital Management
Texas
$260K -$50.5K -2,000 -15%
MSFS
12
Main Street Financial Solutions
Pennsylvania
$188K – – –
Northern Trust
13
Northern Trust
Illinois
$171K +$8.52K +337 +5%
CCM
14
Courage Capital Management
Tennessee
$156K – – –
Millennium Management
15
Millennium Management
New York
$100K -$13.9K -549 -11%
PAG
16
Private Advisor Group
New Jersey
$91.8K +$2.53K +100 +3%
Renaissance Technologies
17
Renaissance Technologies
New York
$81K +$25.7K +1,017 +42%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$77.9K – – –
PTP
19
Platform Technology Partners
New York
$76.3K – – –
GRP
20
Global Retirement Partners
California
$59.1K -$19.7K -780 -28%
MWM
21
Modera Wealth Management
New Jersey
$44.4K +$47.8K +1,890 New
CDH
22
Charles D. Hyman
$38K – – –
Charles Schwab
23
Charles Schwab
California
$36.8K – – –
BFG
24
Bleakley Financial Group
New Jersey
$28.2K – – –
SS
25
Simplicity Solutions
Minnesota
$28.2K +$30.3K +1,200 New
1
2 3

MTNB Hedge Fund Activity: Q1 2023 in Review

50 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2023, worth a combined $12.6M — down 7.4% from $13.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of MTNB and 2 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $77.6K. The largest seller was BlackRock, cutting an estimated $125K.

  • 50 institutional investors held Matinas BioPharma (MTNB) as of Q1 2023, down from 57 in Q4 2022.
  • Funds reported $12.6M of Matinas BioPharma stock for Q1 2023, down 7.4% quarter-over-quarter.
  • 2 funds opened new Matinas BioPharma positions in Q1 2023 and 9 closed out, a net change of -7 holders.
  • The largest Matinas BioPharma buyer in Q1 2023 was Vanguard Group, an estimated $77.6K added.
  • The largest Matinas BioPharma seller in Q1 2023 was BlackRock, an estimated $125K sold.

Based on aggregated 13F filings for Q1 2023.